

Int'l App. No.: PCT/GB00/01520

Int'l Filing Date: 19 April 2000

4. (Amended) A Polymorph according to claim 1, which provides a solid-state  $^{13}\text{C}$  nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.

5. (Amended) A Polymorph according to claim 1, which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.

6. (Amended) A Polymorph according to claim 1, in isolated form.

7. (Amended) A Polymorph according to claim 1, in pure form.

8. (Amended) A Polymorph according to claim 1, in crystalline form.

14. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph according to claim 1 to a human or non-human mammal in need thereof.


#### REMARKS

The above-identified application is being entered into the National Phase from PCT application No. PCT/GB00/01520.

Applicants have amended the claims to put them in conformity with U.S. practice. Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

No new matter has been introduced.

Respectfully submitted,

  
**Yuriy P. Stercho, Ph.D.**  
Attorney for Applicants  
Registration No. 33,797

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5018  
Facsimile (610) 270-5073